Policy & Regulation
Asclepius Meditec's hydrogen oxygen generator AMS-H-03 helps improve COVID-19 disease severity and dyspnea
11 August 2020 -

Chinese medical company Asclepius Meditec reported on Monday the availability of an environmentally friendly treatment generator AMS-H-03 involving the electrolysis of H2O to produce a mixture of hydrogen and oxygen for inhalation by COVID-19 patients with no side effects.

In a multicentered, open-label clinical trial, titled "Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial", the inhalation of the hydrogen/oxygen mixture prevented the further progression of the disease and, most notably, alleviated the shortness of breath experienced by COVID-19 patients. The results of the research as a treatment for COVID-19 were published in the June 2020 edition of the Journal of Thoracic Disease (JTD).

Asclepius Meditec added that the research and clinical trial was conducted on 44 patients with COVID-19 whose dyspnea could not be ameliorated after regular treatment in 11 hospitals. After three days of continuous use of the hydrogen/oxygen generator, AMS-H-03 , all 44 patients showed significant improvement compared with 46 patients who received the standard regimen of oxygen alone.

According to the company, the hydrogen/oxygen generator AMS-H-03 has received the Class III Medical Device certificate from China's National Medical Products Administration. The AMS-H-03 helps to reduce the mortality rate associated with COVID-19.

Login
Username:

Password: